Transpact Enterprises P/B Ratio
Current P/B Ratio
6.2
High Valuation
Very High - Significant premium, high growth expectations or speculative
Transpact Enterprises (TRANSPACT) P/B ratio is 6.2 (High), book value per share ₹ vs Healthcare average P/B of -0.01 — Very High - Significant premium, high growth expectations or speculative. For live price, earnings yield and the full fundamental profile, see TRANSPACT screener.
Current Valuation Metrics
P/B Ratio
6.2
Current Price
₹
Book Value/Share
₹
Exchange
None
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
-0.01
Sector Median
0.62
Sector Rank
#11 of 50
Sector Percentile
22.0%
TRANSPACT P/B Ratio — Valuation Insights & Book Value Analysis
Transpact Enterprises price-to-book ratio interpretation, valuation status and historical context — current P/B 6.2 (High). Read TRANSPACT dividend yield for the complete payout history and dividend yield track record.
- Stock appears overvalued with PB of 6.2, trading at significant premium to book value
- Trading at high premium to book value - indicates strong growth expectations or asset-light business model
- Trading at premium to sector average PB of -0.01
TRANSPACT vs Healthcare Peers — P/B Ratio Comparison
Transpact Enterprises P/B 6.2 vs Healthcare average -0.01, median 0.62 — range -6.55–1.09.
Sector Average
-0.01
Sector Median
0.62
Lowest P/B
-6.55
Highest P/B
1.09
Companies
50
| Company | Symbol | P/B Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Parmax Pharma | PARMAX | -6.55 | ₹46 | Low |
| Span Divergent | SDL | -6.32 | ₹19 | Low |
| Oxygenta Pharmaceutical | OXYGENTAPH | -5.54 | ₹203 | Low |
| Satiate Agri | SATAGRI | -3.39 | ₹8 | Low |
| Adline Chem Lab | ADLINE | -3.03 | ₹5 | Low |
| Bharat Immunologicals | BIBCL | -2.0 | ₹65 | Low |
| Krebs Biochemicals & Ind… | KREBSBIO | -0.82 | ₹129 | Low |
| Cresanto Global | CRESANTO | -0.7 | ₹2 | Low |
| Vivimed Labs | VIVIMEDLAB | -0.21 | ₹50 | Low |
| Triochem Products | TRIPR | 0.04 | ₹0 | Low |